Salem Badr, MD
Interventional Cardiology · Springfield, ILNPI 1396189205
Payments from drug & device makers
What this record shows
This record is dominated by grants: $17,000 of the $24,102 with a category attached, or 70.5%. Medtronic accounts for 79.4% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2021 at $18,791 and has fallen 93.4% since, to $1,233 in 2025.
Across 93 payments — averaging $259.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$19K
- Edwards Lifesciences$2K
- Boston Scientific$934
- Abbott$595
- Abiomed$282
- Teleflex LLC$153
- plus $1K from 13 others
Across 36 payments — averaging $1941.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$39K
- Abbott$19K
- Boston Scientific$12K
What the payments were for
- Grants$17,00071%
- Travel & lodging$1,7667%
- Food & beverage$5,29322%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 32 | $19,137 |
| Edwards Lifesciences | 15 | $1,926 |
| Boston Scientific | 12 | $934 |
| Abbott | 10 | $595 |
| Abiomed | 3 | $282 |
| Teleflex LLC | 1 | $153 |
| Penumbra, Inc. | 1 | $143 |
| W. L. Gore & Associates, Inc. | 1 | $139 |
| Heartflow, Inc. | 1 | $136 |
| Philips North America LLC | 1 | $134 |
| AstraZeneca | 1 | $108 |
| Biotronik Inc. | 1 | $102 |
| Cardinal Health 200 LLC | 2 | $92 |
| Novartis | 5 | $80 |
| Cvrx, Inc. | 2 | $61 |
| Amgen | 2 | $32 |
| Pfizer | 1 | $21 |
| Johnson & Johnson | 1 | $13 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$17,000
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$758
- HawkOne$720
- COREVALVE EVOLUT R$425
- Impella$223
- MitraClip$190
- GUIDELINER$153
- Indigo System$143
- EXCLUDER Conformable AAA Endoprosthesis with Active Control$139
- (6361) Core Mobile$134
- SYNERGY$123
- ENDURANT IIS$122
- COMET$116
- WATCHMAN Access System$114
- Watchman$111
- SAPIEN 3 Ultra RESILIA$104
- AVVIGO Guidance System$103
How this compares
$24,102 in reported general payments places this provider in the 75th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 49 | $79,021 |
| EntrestoSacubitril/Valsartan | 20 | $23,938 |
| FarxigaDapagliflozin Propanediol | 17 | $17,401 |
| JardianceEmpagliflozin | 17 | $15,289 |
| BrilintaTicagrelor | 13 | $11,370 |
| Metoprolol Succinate | 102 | $1,306 |
| Rosuvastatin Calcium | 101 | $1,220 |
| Ranolazine ErRanolazine | 17 | $1,030 |
| ClopidogrelClopidogrel Bisulfate | 98 | $977 |
| Atorvastatin Calcium | 59 | $609 |
| Carvedilol | 50 | $373 |
| Nitroglycerin | 14 | $344 |
| Ezetimibe | 18 | $343 |
| Lisinopril | 48 | $328 |
| Metoprolol Tartrate | 27 | $200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $21 | $79,02149 claims |
| AstraZenecaFarxiga, Brilinta | $108 | $28,77130 claims |
| NovartisEntresto | $80 | $23,93820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 303 interventional cardiology providers in Illinois.
Other interventional cardiology in Springfield
- Tony de MartiniSpringfield$208K
- Shady HenienSpringfield$105K
- Donald YakelSpringfield$54K
- Jack HallSpringfield$40K
- Krishna Rocha SinghSpringfield$25K
- Andrei PopElk Grove Village$900K
- Atman ShahChicago$788K
- Ravi RamanaPalos Park$458K
- Mahesh RajuDowners Grove$281K
- Mark RicciardiEvanston$253K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.